Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Clinical Trial: AZD6234 for Healthy Subjects (NCT05511025) - YouTube
AZD6234 for Obesity Clinical Trial 2025 | Power
Study of AZD9550 and AZD6234 combination for weight loss in people with ...
AstraZeneca’s AZD6234 Study: A Potential Game-Changer for Renal ...
AZD6234 - Drug Targets, Indications, Patents - Synapse
88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R ...
AstraZeneca’s Promising Phase II Study on AZD6234 for Diabetes ...
Efficacy, Safety and Tolerability of AZD6234 in Participants Living ...
AZD6234 in Obesity and Endocrinology and Diabetes, Type II - Clinical ...
AstraZeneca: Strong Growth Potential And Market Volatility Offer ...
阿斯利康：GLP-1/GCG+Amylin启动减重2b期临床
(PDF) AZD6234, a novel selective amylin receptor agonist (SARA ...
(PDF) Characterisation of AZD6234, a novel amylin receptor selective ...
Dose-effect relationships of AZD6244:BEZ235 combinations on apoptosis ...
(A) Antitumor-growth ability of AZD6244. (B) The single AZD6244 ...
AstraZeneca Presents Promising Early Data on Oral GLP-1 Agonist AZD5004 ...
4周减重九斤！阿斯利康披露口服小分子GLP-1药物的最新数据，超18亿美元合作有望兑现_腾讯新闻
AZD6234注射液临床Ⅱ期随机化双盲试验_摩熵医药
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in ...
Heterogeneity in AZD6244-induced DNA synthesis inhibition in colorectal ...
AZD6234(AZD6234) - 药物靶点：AMYR_在研适应症：超重，2型糖尿病，肥胖_专利_临床_研发
诚益生物与阿斯利康就小分子GLP-1R激动剂ECC5004达成独家合作
诚益生物与阿斯利康就小分子GLP-1R激动剂ECC5004达成独家合作 - 知乎
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase ...
Design, Synthesis, and Biological Evaluation of Potent and Selective ...
Discussing AstraZeneca's Brain-penetrating KRAS Inhibitor
高达20亿美金！阿斯利康引进诚益生物下一代口服GLP-1R激动剂医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? | The Motley Fool
Recent Advances of Cell-Penetrating Peptides and Their Application as ...
AZD6234注射液临床Ⅱ期随机化双盲试验_摩熵医药(原药融云)
今年终止2款GLP-1开发：AZ从中国13.5亿首付款引进GLP-1_摩熵医药
AZD-9550(AZD-9550) - 药物靶点：GCGR x GLP-1R_在研适应症：肥胖，2型糖尿病，非酒精性脂肪性肝炎_专利_临床_研发
Effect of AZD6244 on acrolein-induced inflammasome activation and ...
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell ...
AZD6244 reduces tumor growth and angiogenesis without hepatic and renal ...
Antitumor activity of simvastatin and AZD6244 on cell proliferation and ...
Select prospective phase II trials of multi-targeted tyrosine kinase ...
The ATR inhibitor (AZD6738) and olaparib are synergistic in ...
Figure 3 from The Mitogen-Activated Protein/Extracellular Signal ...
GLP1R/GCGR 双激动剂 + 胰淀素类似物！阿斯利康肥胖联合疗法国内申报临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
AZD6244 inhibits proliferation of gastric cancer cells.: The ...
How does AstraZeneca's PARP inhibitor differentiate?
Anti-obesity drug development: Industry trends in 2024 | Gubra
Using DNA to Identify an Amino Acid Sequence | Study.com
GLP-1减肥药“换了人间”_财富号_东方财富网
The orally active and bioavailable ATR kinase inhibitor AZD6738 ...
Myocardial Steatosis and Necrosis in Atria and Ventricles of Rats Given ...
Combination of AZD6244 with IMiDs triggers synergistic antimyeloma ...
RAF inhibition overcomes acquired resistance to AZD6244 in C6244-R1 ...
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a ...
阿斯利康也“Follow”第一三共 - 知乎
阿斯利康GLP1R-GCGR双重激动剂及胰淀素类似物联合疗法在国内申请临床用于治疗肥胖
Computational Study on New Natural Compound Inhibitors of Pyruvate ...
AZD6244 resistant cell lines can be sensitised with combined inhibition ...
AZD9574 selectively inhibits and traps PARP1. A, Chemical structure of ...
A study to assess the safety, tolerability, pharmacokinetics, and ...
阿斯利康：GLP-1/GCG+Amylin启动减重2b期临床 Armstrong 2025年3月6日， 阿斯利康 在 ...
Pre-treatment of cancer cells with the MEK inhibitor AZD6244 impairs ...
Recent Advances in the Discovery of Nicotinic Acetylcholine Receptor ...
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein ...
In vitro activity of AZD6244 plus rapamycin combination. Around 80% ...
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (2)
Chemical structures of investigated adenosine receptor agonists ...
Optimisation of biphenyl acetic acid inhibitors of diacylglycerol ...
Identification of AZD6244 as a potential enhancer for combination ...
Structure activity relationship of 2-arylalkynyl-adenine derivatives as ...
A structural basis for amylin receptor phenotype | Science
TrialSummaries.com - A study to assess the safety, tolerability ...
In vivo therapeutic efficacy of AZD6244 in combination with ...
Frontiers | Current Developments on the Role of α1-Adrenergic Receptors ...
Journal of Medicinal Chemistry
Frontiers | Effects of semaglutide on vascular structure and proteomics ...
康诺亚/阿斯利康：Claudin18.2 ADC启动全球三期临床 Armstrong 2024年3月7日， 阿斯利康 在药品临床试验登记与信息 ...
开启“减重、不减肌肉”新篇章？选择性胰淀素受体激动剂AZD6234最新研究亮相2025EASD_2025EASD_医脉通
AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist ...
Tumor growth inhibition in vivo, by AZD6244 and TRAIL treatment, is ...
Opportunities for Small Molecules in Cancer Immunotherapy: Trends in ...
The potent and selective α4β2*/α6*‐nicotinic acetylcholine receptor ...
:%0A%0AAZD6234%20for%20Obesity.png?md=1)
